News | December 09, 2009

Dose Escalation Achieved, Sparing Healthy Tissue

December 10, 2009 - Better dose conformality can be reached with intensity-modulated radiotherapy (IMRT) in comparison to three-dimensional conformal radiotherapy techniques - as used in dose escalation studies - offering an additional opportunity for healthy tissue protection, reports Michael Pinkawa, M.D., in an abstract of his study published in UroToday.com.

The study's objective is to compare the dose distribution in IMRT treatment plans with and without a simultaneous integrated boost (IB) after performing a PET/CT with 18F-choline for treatment planning. Dose-volume histograms and equivalent uniform doses (EUD) were evaluated and normal tissue complication probability (NTCP) for the bladder and rectum compared.

Dr. Pinkawa found that while improved biochemical control rates for prostate cancer have been consistently shown in randomized three-dimensional (3D) conformal radiotherapy dose escalation studies, this benefit was associated with the problem of increased rectal toxicity. The increasing implementation of image-guided radiotherapy (IGRT) allows a reduction of safety margins around the clinical target volume (CTV). Thus, the same or improved local tumor control with lower rectal toxicity due to reduced rectal volume within the target volume can be expected.

Dr. Pinkawa also points to dose-painting as another advantage associated with IMRT as areas with a higher risk of tumor recurrence or a higher tumor load can be covered with larger doses in the same fraction. In view of an often multifocal micrsoscopic spread of prostate cancer - not possible to delineate with the presently available imaging modalities - the whole prostate must still be covered by an effective dose.

He found that treatment planning with a simultaneous integrated boost allows an individually adapted dose escalation. The boost volume, as defined by a tumor-to-background uptake ratio >2 in a PET/CT with choline, correlated with several well-established prognostic parameters. His founding indicated that the therapeutic ratio can be improved by a considerable dose escalation to the macroscopic tumor site without considerably increasing the NTCP for the rectum and bladder.

For more information: www.urotoday.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init